Please login to the form below

Not currently logged in
Email:
Password:

Recordati

This page shows the latest Recordati news and features for those working in and with pharma, biotech and healthcare.

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease

Recordati Rare Disease has revealed new data from a phase 3 trial of its Cushing’s disease treatment Isturisa. ... The normalisation of mUFC levels represents an ‘important’ treatment goal, Recordati said in a statement, by potentially reducing

Latest news

More from news
Approximately 5 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    AstraZeneca, Takeda, Astellas Pharma, Novo Nordisk and Recordati take up the final five positions, though only two - Takeda (3.9%) and Astellas (9.3%) - recorded growth.

  • Deal Watch July 2016 Deal Watch July 2016

    BioD. $21.3 plus $56.5 contingent. $22m. 3.5x. N/A. Recordati. Pro Farma. ... Recordati has been busy on the acquisition front recently; in May the company acquired Italichimici for $145m, strengthening its gastroenterology and respiratory ranges, and

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    4. ). 63. Apricus Biosciences (formerly NexMed) / Recordati. Licence. Vitaros topical treatment for erectile dysfunction.

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    246. Laboratorios Casen Fleet/ Recordati. Acquisition. Spanish pharmaceutical company. 123. Pacific Biosciences of California/Roche Diagnostics.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    50. Opalia Pharma / Recordati . Acquisition of 90% stake. Branded generic drugs - dermatology, GI, respiratory.

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Recordati promotes Andrea Recordati to COO Recordati promotes Andrea Recordati to COO

    Milan-based pharmaceutical company Recordati has promoted Andrea Recordati (pictured right) to chief operating officer. ... In his newly-created position, Andrea Recordati will be responsible for all the group's commercial and production activities.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....